GRAL news sentiment

#3113Tone

TradingViewDirect company coverageStored article

Lost Money on Grail, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact SueWallSt

SueWallSt is announcing a securities class action lawsuit against Grail, Inc. (GRAL) on behalf of shareholders who experienced significant losses after the company's NHS-Galleri trial failed to meet its primary endpoint. Investors are encouraged to seek lead plaintiff status by August 4, 2026, though class members can still participate in a settlement even if they miss this deadline. The lawsuit alleges that Grail made misleading statements about the trial's progress and expected outcomes, leading to a 50.55% stock drop when the failure was disclosed.

FinanceLife Sciences

Published

23 Jul 2026 14:10

News subject

Regulatory and legal

Why this score

Failed To Meet, Legal or regulatory risk, Negative market reaction

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 2.2% · 21.7d old

Duplicates

2 consolidated

#3215Tone

GlobeNewswireDirect company coverageStored article

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against GRAIL, Inc. (GRAL)

Bernstein Liebhard LLP has announced a securities class action lawsuit filed against GRAIL, Inc. on behalf of investors who purchased common stock between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made false and misleading statements, leading to artificially inflated stock prices and significant losses for investors. Shareholders are encouraged to join the lawsuit, with a lead plaintiff deadline of August 4, 2026.

FinanceLife Sciences

Published

23 Jul 2026 13:10

News subject

Regulatory and legal

Why this score

Legal or regulatory risk

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.9% · 21.7d old

Duplicates

1 consolidated

#3318Tone

GlobeNewswireDirect company coverageStored article

GRAIL, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 4, 2026

Bernstein Liebhard LLP reminds investors of GRAIL, Inc. (NASDAQ: GRAL) that they have until August 4, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements between May 13, 2025, and February 19, 2026, causing investors to suffer losses. Investors who purchased shares during this period and wish to serve as lead plaintiff must file papers by the deadline.

Financial MarketsFinance

Published

22 Jul 2026 13:42

News subject

Regulatory and legal

Why this score

Legal or regulatory risk

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.7% · 22.7d old

Duplicates

1 consolidated

#3414Tone

MorningstarDirect company coverageStored article

GRAL Deadline Alert: Levi & Korsinsky Reminds Grail, Inc. (GRAL) Investors of Securities Class Action Deadline on August 4, 2026

Levi & Korsinsky reminds investors of Grail, Inc. (NASDAQ: GRAL) that the deadline to apply for lead plaintiff in a securities class action lawsuit is August 4, 2026. This lawsuit follows a significant stock drop after Grail's NHS-Galleri trial failed its primary endpoint, resulting in losses of over 50% for investors who purchased securities between May 13, 2025, and February 19, 2026. The firm encourages affected shareholders to contact them to evaluate their eligibility to recover losses or serve as a lead plaintiff.

FinanceFinancial MarketsLife Sciences

Published

22 Jul 2026 13:42

News subject

Regulatory and legal

Why this score

Legal or regulatory risk, Negative market reaction

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 2.5% · 22.7d old

Duplicates

5 consolidated

#3516Tone

PR NewswireDirect company coverageStored article

INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman

Hagens Berman is investigating GRAIL, Inc. (NASDAQ: GRAL) for alleged securities law violations in connection with its NHS-Galleri cancer screening trial. The lawsuit claims GRAIL misled investors about the trial's design and efficacy, particularly regarding the adequacy of the three-year follow-up period, leading to a significant stock drop after the trial failed its primary endpoint. Investors who suffered substantial losses are encouraged to come forward and have until August 4, 2026, to seek lead plaintiff status.

FinanceLife Sciences

Published

21 Jul 2026 20:11

News subject

Regulatory and legal

Why this score

Legal or regulatory risk, Negative market reaction

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.8% · 23.4d old

Duplicates

2 consolidated

#3625Tone

WBOC TVDirect company coverageStored article

Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors

The Portnoy Law Firm has announced a class action lawsuit on behalf of investors who purchased Grail, Inc. (NASDAQ: GRAL) securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail disseminated false and misleading statements about the NHS-Galleri trial, concealing that the trial period was insufficient to achieve its primary endpoint of reducing Stage III-IV cancers. Investors have until August 4, 2026, to file a lead plaintiff motion.

Life SciencesFinance

Published

21 Jul 2026 14:10

News subject

Regulatory and legal

Why this score

Legal or regulatory risk

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 0.9% · 23.7d old

Duplicates

1 consolidated

#3750Tone

TradingViewDirect company coverageStored article

Enterprise value to EBIT forward of GRAIL, Inc. – NASDAQ:GRAL

This article from TradingView provides a financial metric for GRAIL, Inc. (NASDAQ: GRAL), specifically its enterprise value to EBIT (Earnings Before Interest and Taxes) forward. The content is primarily a title and navigational elements, indicating the company's listing on the Nasdaq Stock Market under the Health Technology sector. The presented information is limited to the company name and the financial metric.

Financial MarketsLife SciencesEarnings

Published

21 Jul 2026 11:10

News subject

Earnings

Why this score

No clear positive or negative phrase

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 0.1% · 23.8d old

Duplicates

1 consolidated

#3812Tone

PR NewswireDirect company coverageStored article

Lawsuit Notice: $GRAL Legal News: GRAIL, Inc. Trial Results and 50% Stock Drop Trigger Securities Fraud Class Action

Bleichmar Fonti & Auld LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. and its executives. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, causing a 50.55% stock drop on February 20, 2026, after the trial failed to meet its primary endpoint. Investors who purchased GRAIL stock are encouraged to contact the law firm to learn about their legal options, with a lead plaintiff deadline of August 4, 2026.

Life SciencesFinance

Published

21 Jul 2026 10:10

News subject

Regulatory and legal

Why this score

Failed To Meet, Legal or regulatory risk, Negative market reaction

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 2% · 23.8d old

Duplicates

1 consolidated

#3916Tone

GlobeNewswireDirect company coverageStored article

Deadline Alert: Grail, Inc. (GRAL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP reminds investors of Grail, Inc. (GRAL) about an upcoming August 4, 2026 deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges that Grail made misleading statements during the Class Period of May 13, 2025, to February 19, 2026, regarding its NHS-Galleri Trial, after which the stock price dropped significantly. Investors who suffered losses are encouraged to contact the firm to inquire about pursuing claims.

FinanceLife Sciences

Published

21 Jul 2026 08:11

News subject

Regulatory and legal

Why this score

Legal or regulatory risk, Negative market reaction

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.7% · 23.9d old

Duplicates

3 consolidated

#4025Tone

GlobeNewswireDirect company coverageStored article

Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Role

Bragar Eagel & Squire, P.C. has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) on behalf of investors who purchased shares between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made false or misleading statements regarding its NHS Galleri trial, specifically concerning the insufficiency of the trial period to demonstrate a reduction in Stage III-IV cancers. Investors have until August 4, 2026, to apply to be appointed as lead plaintiff.

FinanceLife Sciences

Published

20 Jul 2026 22:09

News subject

Regulatory and legal

Why this score

Legal or regulatory risk

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.2% · 24.3d old

Duplicates

1 consolidated

#419Tone

GlobeNewswireDirect company coverageStored article

GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky

Levi & Korsinsky, LLP has issued a shareholder alert for Grail, Inc. (NASDAQ: GRAL) investors, announcing a securities class action lawsuit. The lawsuit alleges that Grail misled investors regarding its NHS-Galleri trial, which was projected to achieve a statistically significant reduction in late-stage cancers but failed to meet its primary endpoint, causing a 50.55% stock drop. Investors who purchased shares during the Class Period (May 13, 2025, through February 19, 2026) are encouraged to contact the law firm to learn about recovering their losses.

Life SciencesFinance

Published

20 Jul 2026 14:40

News subject

Regulatory and legal

Why this score

Failed To Meet, Legal or regulatory risk, Negative market reaction

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.9% · 24.6d old

Duplicates

1 consolidated

#4214Tone

GlobeNewswireDirect company coverageStored article

GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS

Hagens Berman is investigating a securities class action against GRAIL, Inc. (GRAL) following a $2.2 billion market cap wipeout after its NHS-Galleri cancer screening trial failed to meet its primary endpoint. The lawsuit alleges that GRAIL misled investors by concealing insufficient trial design and withholding critical data regarding the efficacy and timeline of the study. Investors who suffered losses between May 13, 2025, and Feb. 19, 2026, are encouraged to come forward by the lead plaintiff deadline of August 4, 2026.

FinanceFinancial MarketsLife Sciences

Published

20 Jul 2026 09:44

News subject

Regulatory and legal

Why this score

Failed To Meet, Legal or regulatory risk

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.6% · 24.8d old

Duplicates

2 consolidated

#4315Tone

The National Law ReviewDirect company coverageStored article

GRAL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that GRAIL, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and certain officers. The lawsuit claims that defendants made misleading statements between May 13, 2025, and February 19, 2026, regarding the likelihood of success in Grail's NHS-Galleri trial. Investors who suffered losses are encouraged to join the case and have until August 4, 2026, to request to be appointed as lead plaintiff.

FinanceLife Sciences

Published

19 Jul 2026 05:09

News subject

Regulatory and legal

Why this score

Legal or regulatory risk

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.1% · 26.0d old

Duplicates

1 consolidated

#4433Tone

Key Biscayne PortalDirect company coverageStored article

GRAIL, Inc. Deadline: GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit

The Rosen Law Firm reminds purchasers of GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, that they have an opportunity to lead a securities fraud class action lawsuit. Investors who bought GRAIL common stock during this period can seek compensation without upfront fees, and the deadline to move the Court to serve as lead plaintiff is August 4, 2026. The lawsuit alleges that GRAIL provided misleading positive statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial results, causing damages to investors.

FinanceLife Sciences

Published

18 Jul 2026 19:40

News subject

Regulatory and legal

Why this score

Legal or regulatory risk

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 0.7% · 26.4d old

Duplicates

2 consolidated

#4525Tone

GlobeNewswireDirect company coverageStored article

GRAIL, INC. DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL,

The Rosen Law Firm is reminding investors who purchased GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, about the August 4, 2026 lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial's sufficiency in demonstrating cancer reduction. Investors are encouraged to secure counsel to pursue potential compensation.

FinanceLife Sciences

Published

17 Jul 2026 23:40

News subject

Regulatory and legal

Why this score

Legal or regulatory risk

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 0.9% · 27.3d old

Duplicates

1 consolidated

#4615Tone

TMX NewsfileDirect company coverageStored article

GRAL INVESTOR DEADLINE: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against GRAIL, Inc. for alleged violations of the Securities Exchange Act of 1934. Investors who purchased GRAL common stock between May 13, 2025, and February 19, 2026, and suffered substantial losses, have until August 4, 2026, to seek appointment as lead plaintiff. The lawsuit claims Grail made misleading statements regarding its NHS-Galleri trial's primary endpoint, which ultimately failed to show a statistically significant reduction in late-stage cancers.

Life SciencesFinance

Published

17 Jul 2026 19:50

News subject

Regulatory and legal

Why this score

Legal or regulatory risk

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1% · 27.4d old

Duplicates

1 consolidated

#4750Tone

Stock TitanDirect company coverageStored article

Director at GRAIL, Inc. (GRAL) receives 427 deferred stock units in fee swap

GRAIL, Inc. Director Gregory L. Summe was granted 427 deferred stock units (DSUs) as compensation, valued at $31,787.67, in lieu of cash director fees. The DSUs, priced at $74.36 per unit, vested immediately on July 15, 2026, and increased his direct holdings to 45,672 shares. This transaction was reported in a Form 4 filing and summarized by Rhea-AI.

FinanceEarningsLife SciencesFinancial Markets

Published

16 Jul 2026 21:11

News subject

Earnings

Why this score

No clear positive or negative phrase

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · <0.1% · 28.4d old

Duplicates

1 consolidated

#4850Tone

Stock TitanDirect company coverageStored article

GRAIL, Inc. (GRAL) director receives 276 deferred stock units as fees

GRAIL, Inc. director William J. Chase was granted 276 deferred stock units on July 15, 2026, as compensation for director fees, totaling $20,568.49. These units, priced at $74.36 per share, vested immediately, increasing his direct holdings to 42,978 shares. This transaction was reported in a Form 4 filing and represents a conversion of cash fees into equity under the company's 2024 Equity Incentive Plan.

FinanceLife Sciences

Published

16 Jul 2026 21:11

News subject

Market update

Why this score

No clear positive or negative phrase

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · <0.1% · 28.4d old

Duplicates

1 consolidated

#4912Tone

GlobeNewswireDirect company coverageStored article

GRAL Investor Alert: HBSS Probes GRAIL, Inc. (GRAL) Following Securities Class Action Over Failed NHS-Galleri Trial

Hagens Berman is investigating GRAIL, Inc. (GRAL) following a class action lawsuit alleging the company misled investors about the design and efficacy of its NHS-Galleri cancer screening trial. The lawsuit claims GRAIL concealed inadequate trial design and withheld critical data, leading to a significant stock price collapse after the trial failed to meet its primary endpoint. Investors who suffered losses are encouraged to submit their claims by August 4, 2026.

EarningsFinanceFinancial MarketsLife Sciences

Published

16 Jul 2026 18:11

News subject

Regulatory and legal

Why this score

Failed To Meet, Legal or regulatory risk

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.2% · 28.5d old

Duplicates

2 consolidated

#5025Tone

www.marketscreener.comDirect company coverageStored article

GRAIL, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs GRAIL, Inc. (GRAL) Investors of a Securities Fraud Lawsuit

Berger Montague PC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) on behalf of investors who purchased shares between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL concealed material inadequacies in the NHS-Galleri trial design, leading to the trial's failure to achieve its primary endpoint. Following this announcement, GRAIL's stock plummeted by over 50%.

FinanceFinancial MarketsLife Sciences

Published

16 Jul 2026 14:10

News subject

Regulatory and legal

Why this score

Legal or regulatory risk

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 0.7% · 28.7d old

Duplicates

1 consolidated

#5111Tone

PR NewswireDirect company coverageStored article

GRAL DEADLINE: SueWallSt Reminds Grail, Inc. Investors of Upcoming Securities Class Action Deadline

SueWallSt is reminding investors of Grail, Inc. (NASDAQ: GRAL) about an upcoming securities class action deadline of August 4, 2026. The lawsuit alleges that Grail's leadership withheld detailed results from the NHS-Galleri trial, leading to a 50.55% stock plunge after the trial failed to meet its primary endpoint. Investors who purchased GRAL stock between May 13, 2025, and February 19, 2026, and suffered losses, may be eligible to join the lawsuit.

FinanceLife Sciences

Published

16 Jul 2026 14:10

News subject

Regulatory and legal

Why this score

Failed To Meet, Legal or regulatory risk, Negative market reaction

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.3% · 28.7d old

Duplicates

1 consolidated

#5243Tone

PR NewswireDirect company coverageStored article

Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer Plans

Priority Health, a leading Michigan health plan, has partnered with GRAIL to offer the Galleri multi-cancer early detection blood test to its self-insured employer groups, making it the first in Michigan to do so. This expansion follows Priority Health's earlier integration of Galleri into its Medicare Advantage plans, aiming to improve early cancer detection, reduce healthcare costs, and enhance patient outcomes by identifying cancers before symptoms appear. The Galleri test screens for over 50 cancer types with a simple blood draw, complementing existing standard-of-care screenings.

Life Sciences

Published

16 Jul 2026 13:10

News subject

Market update

Why this score

Negative financial language

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · <0.1% · 28.7d old

Duplicates

1 consolidated

#5318Tone

GlobeNewswireDirect company coverageStored article

GRAIL, INC. (GRAL) SHAREHOLDER ALERT Bernstein Liebhard LLP

Bernstein Liebhard LLP has issued a shareholder alert reminding investors of GRAIL, Inc. (NASDAQ: GRAL) about an upcoming August 4, 2026 deadline for a securities fraud class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements between May 13, 2025, and February 19, 2026, leading to artificially inflated stock prices and significant losses for investors. Investors who purchased shares during this period and suffered losses are encouraged to act promptly.

Finance

Published

16 Jul 2026 13:10

News subject

Regulatory and legal

Why this score

Legal or regulatory risk

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 0.9% · 28.7d old

Duplicates

1 consolidated

#5421Tone

The National Law ReviewDirect company coverageStored article

GRAL STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) and its officers. The lawsuit alleges that GRAIL made materially false and misleading statements regarding the likelihood of achieving the primary endpoint in its NHS-Galleri trial between May 13, 2025, and February 19, 2026. Investors with substantial losses are encouraged to come forward by August 4, 2026, to potentially lead the class action.

FinanceLife Sciences

Published

16 Jul 2026 10:10

News subject

Regulatory and legal

Why this score

Legal or regulatory risk

Company focus

Company discussed · 86%

How it is used

Direct company coverage

Weighted influence

Low · 0.6% · 28.8d old

Duplicates

1 consolidated

#5513Tone

MorningstarDirect company coverageStored article

GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Levi & Korsinsky, LLP has announced a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL) for alleged misrepresentations concerning its NHS-Galleri trial. The lawsuit claims that the trial's three-year design was insufficient to achieve its primary endpoint of reducing late-stage cancers, leading to a significant stock price drop. Investors who purchased GRAL securities between May 13, 2025, and February 19, 2026, and incurred losses may be eligible to join the class action.

FinanceLife Sciences

Published

15 Jul 2026 13:39

News subject

Regulatory and legal

Why this score

Legal or regulatory risk, Negative market reaction

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.3% · 29.7d old

Duplicates

2 consolidated

#5620Tone

GlobeNewswireDirect company coverageStored article

$GRAL Investor Loss Alert: GRAIL, Inc. Investors may have been Misled after Channel Stuffing Claims Lead to 50% Stock Drop – Contact BFA Law if You Lost Money

A class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and its executives for securities fraud after its stock dropped 50%. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, which failed to meet its primary endpoint of reducing late-stage cancers. Investors who suffered losses are encouraged to contact Bleichmar Fonti & Auld LLP by August 4, 2026, to discuss their legal options.

FinanceLife SciencesFinancial Markets

Published

15 Jul 2026 06:17

News subject

Regulatory and legal

Why this score

Failed To Meet, Legal victory, Legal or regulatory risk, Negative market reaction

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1% · 30.0d old

Duplicates

1 consolidated